182 related articles for article (PubMed ID: 26141305)
21. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study.
Matorras R; Prieto B; Exposito A; Mendoza R; Crisol L; Herranz P; Burgués S
Reprod Biomed Online; 2009 Dec; 19(6):879-87. PubMed ID: 20031032
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone for in vitro fertilisation (IVF).
Sood A; Mohiyiddeen G; Ahmad G; Fitzgerald C; Watson A; Mohiyiddeen L
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD000099. PubMed ID: 34808697
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Best Pract Res Clin Obstet Gynaecol; 2023 Jul; 89():102350. PubMed ID: 37320996
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study.
Sydow P; Gmeinwieser N; Pribbernow K; Keck C; Wiegratz I
Reprod Biol Endocrinol; 2020 May; 18(1):54. PubMed ID: 32456636
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
26. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial.
Wang Y; Kuang Y; Chen Q; Cai R
Trials; 2018 Aug; 19(1):455. PubMed ID: 30134964
[TBL] [Abstract][Full Text] [Related]
27. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
Youssef MA; Abou-Setta AM; Lam WS
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
[TBL] [Abstract][Full Text] [Related]
28. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of recombinant human granulocyte colony-stimulating factor in patients with poor ovarian response: protocol for a multicentre, randomised, controlled trial.
Zeng X; Du L; Yang H; Wang F
BMJ Open; 2023 Dec; 13(12):e074135. PubMed ID: 38159964
[TBL] [Abstract][Full Text] [Related]
30. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
31. Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.
Kaplan S; Levy-Toledano R; Davies M; Roy D; Howles CM; Lass A
Front Endocrinol (Lausanne); 2021; 12():632674. PubMed ID: 33815290
[TBL] [Abstract][Full Text] [Related]
32. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.
Lehert P; Arvis P; Avril C; Massin N; Parinaud J; Porcu G; Rongières C; Sagot P; Wainer R; D'Hooghe T
Hum Reprod; 2021 May; 36(6):1600-1610. PubMed ID: 33860313
[TBL] [Abstract][Full Text] [Related]
33. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
Kwan I; Bhattacharya S; Kang A; Woolner A
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD005289. PubMed ID: 25150465
[TBL] [Abstract][Full Text] [Related]
35. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.
Choi BC; Zhou C; Ye H; Sun Y; Zhong Y; Gong F; Sini I; Abramova N; Longobardi S; Hickey M; D'Hooghe T
Reprod Biol Endocrinol; 2022 Jan; 20(1):15. PubMed ID: 35039049
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
Kwan I; Bhattacharya S; McNeil A; van Rumste MM
Cochrane Database Syst Rev; 2008 Apr; (2):CD005289. PubMed ID: 18425917
[TBL] [Abstract][Full Text] [Related]
37. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
[TBL] [Abstract][Full Text] [Related]
38. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients.
Qiao J; Zhang Y; Liang X; Ho T; Huang HY; Kim SH; Goethberg M; Mannaerts B; Arce JC
Hum Reprod; 2021 Aug; 36(9):2452-2462. PubMed ID: 34179971
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol.
Jayaprakasan K; Narkwichean A; Maalouf WE; Campbell BK
BMJ Open; 2014 Oct; 4(10):e005767. PubMed ID: 25296654
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).
Kwan I; Bhattacharya S; Woolner A
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD005289. PubMed ID: 33844275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
